BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px
Document › Details

PerkinElmer, Inc.. (3/28/06). "Press Release: PerkinElmer and George Mason University Announces Alliance to Develop Novel Proteomic Technologies and Enable Biomarker Identification for Early Cancer Detection, PerkinElmer’s BioXpression™ Platform to Be Us

Organisations Organisation PerkinElmer Inc. (NYSE: PKI)
  Group PerkinElmer (Group)
  Organisation 2 George Mason University, Center for Applied Proteomics and Molecular Medicine (CAPMM)
  Group George Mason University
Product Product biomarker
Index term Index term PerkinElmer–George Mason Univ: cancer biomarkers, 200603– collab 5y research identification of biomarkers for early cancer detection
Person Person Friel, Robert F. (PerkinElmer 200802– CEO before COO before President Life+Analytical joined 1999 as CFO)

PerkinElmer, Inc. (NYSE: PKI), a global technology leader in Health Sciences and Photonics, announced today a five-year research collaboration agreement with George Mason University to develop a new and innovative approach for cancer detection and risk stratification. Scientists from both organizations will work together on the design of several new types of clinical assay platforms that utilize both the amino acid identification of a protein fragment and its specific mass to identify the biomarker. Areas of focused research include Stage I lung, ovarian and breast cancers.

"For improved patient outcomes, new diagnostics are needed," said Robert F. Friel, president, PerkinElmer Life and Analytical Sciences. "We are excited to provide technology that enables proteomic researchers to identify new biomarkers that may be able to detect cancer earlier. Collaborating with George Mason University's Center for Applied Proteomics and Molecular Medicine provides an excellent opportunity to combine the superior technology of PerkinElmer and the systems biology research approach of this great institution."

The alliance initially calls for the creation of a new proteomics technology to accurately measure and detect specific protein fragments found in human blood, which are potential biomarkers for disease. The alliance builds on a recent discovery by George Mason University researchers, Drs. Emanuel F. Petricoin and Lance A. Liotta, of an archive of protein fragments in human blood.

"This untapped archive of protein fragments from diverse tissue and cellular origins may offer vital disease-related information," theorized Liotta. "High-abundance proteins, such as albumin, found in blood serum appear to act as molecular magnets that mop up the fragments, and our work to date demonstrates that these fragments can be identified, measured and analyzed in the context of specific diseases, such as early stage ovarian cancer."

Petricoin explained that the alliance goes beyond the rigorous validation and discovery of new markers for cancer to a new and unprecedented paradigm for disease detection using a new type of biomarker. "The new concept - that disease detection lies in the information stored in fragments of proteins - requires both the precise mass and the amino acid sequence of the candidate biomarker," he said.

The biomarker candidates that George Mason scientists are discovering utilizing PerkinElmer's BioXPRESSION platform will then be validated in large-scale clinical trials to determine whether they identify the presence of cancer, discriminate cancer from other benign diseases and/or determine that a person does not have cancer.

"This research agreement with PerkinElmer will become a major driver in the rapidly emerging field of proteomics and represents the first commercial venture of this magnitude for the university," says George Mason President Alan Merten. "But more importantly, it is an opportunity to meld the international reputations of George Mason scientists with the globally respected expertise of PerkinElmer to develop new technologies for clinical research that might ultimately reduce suffering caused by cancer and save lives."

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information

Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.5 billion in 2005, has 8,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through or 1-877-PKI-NYSE.

George Mason University is the largest public university in Virginia, serving more than 29,000 students in 148 degree programs. Research expenditures have tripled during the past 10 years and continue to grow. Located just minutes from the nation's capital, Mason is positioned to reach out to the world as a center of inquiry, knowledge and professional expertise in fields with vital implications for human needs and future opportunities.


Investor Relations:
Steven Delahunt
PerkinElmer, Inc.
(781) 431-4258
Media Contact:
Kevin Lorenc
PerkinElmer, Inc.
(203) 402-6890

Record changed: 2016-03-19


BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px

More documents for PerkinElmer (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

» top


Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 120x180px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture [LSE] – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px